Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines - PubMed
3 hours ago
- #Cross-Reactive Immunity
- #Bundibugyo Virus
- #Ebola Vaccines
- Licensed Zaire ebolavirus (EBOV) vaccines, such as rVSV-ZEBOV-GP and Ad26.ZEBOV/MVA-BN-Filo, induce cross-reactive antibody responses against Bundibugyo virus (BDBV).
- Cross-reactive BDBV antibody levels are detectable but substantially lower than homologous EBOV responses across vaccine groups, timepoints, and age categories.
- BDBV responses increased over time in the Ad26.ZEBOV/MVA-BN-Filo regimen, suggesting evolving heterologous immunity.
- Findings support the plausibility of partial protection against BDBV with existing EBOV vaccines, highlighting their potential use in BDBV outbreaks in absence of approved BDBV-specific vaccines.
- Study reinforces the need for broadly protective pan-filovirus vaccines to address multiple filovirus threats.